FDA approve new daily pill for common skin cancer
from Medical News Today
Taken in the form of a daily pill, Odomzo is marketed by Novartis AG — a Swiss pharma giant with U.S. headquarters in East Hanover, New Jersey. The U.S. Food and Drug Administration say a trial showed the drug shrank or wiped out tumors in 58 percent of patients treated.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063